Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Chronic Lymphoid Leukemia

Tundra lists 4 Chronic Lymphoid Leukemia clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT03766763

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Open label, single arm, multicenter phase II trial.

Gender: All

Ages: 18 Years - Any

Updated: 2025-11-26

Chronic Lymphoid Leukemia
ACTIVE NOT RECRUITING

NCT04515238

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

CLL2-BZAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.

Gender: All

Ages: 18 Years - Any

Updated: 2025-06-10

Chronic Lymphoid Leukemia
ACTIVE NOT RECRUITING

NCT04608318

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in patients with previously untreated CLL.

Gender: All

Ages: 18 Years - Any

Updated: 2024-12-31

Chronic Lymphoid Leukemia
RECRUITING

NCT03852407

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).

Gender: All

Ages: 18 Years - 75 Years

Updated: 2022-10-12

Acute Myeloid Leukemia in Remission
Myelodysplastic Syndromes
Chronic Myeloid Leukemia in Remission
+7